{"id":"W2898437318","doi":"10.1093/ofid/ofy210.552","title":"544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial","year":2018,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Dosing; Regimen; Viral load; Flow cytometry; Gastroenterology; Pharmacology; Internal medicine; Adverse effect; Human immunodeficiency virus (HIV); Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008194409,0.0001844183,0.0004433506,0.0001068656,0.0001761004,0.00006139676,0.0002814112,0.00005665473,0.01347509],"category_scores_gemma":[0.0001499243,0.0001431627,0.000188434,0.0002551734,0.0003092552,0.0001574789,0.0003359024,0.0001252565,0.000412916],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004361834,"about_ca_system_score_gemma":0.0002916469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002048824,"about_ca_topic_score_gemma":0.00007658797,"domain_scores_codex":[0.9984816,0.00008110166,0.0003429583,0.0003311345,0.0003936498,0.0003694952],"domain_scores_gemma":[0.9988804,0.0001141644,0.0001198579,0.0003223151,0.0002306888,0.0003325421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4032892,0.01635106,0.1386095,0.0003509939,0.001613428,0.0002695331,0.0003601898,0.000001404605,0.02279628,0.002706977,0.2396281,0.1740234],"study_design_scores_gemma":[0.4816843,0.03612537,0.03623121,0.0006192849,0.001506571,0.0001264804,0.0003162261,0.001688852,0.08400553,0.007977081,0.3486422,0.001076904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9243023,0.0004154897,0.00003056019,0.0006848574,0.0003965408,0.001788322,0.0009173031,0.00005486644,0.0714097],"genre_scores_gemma":[0.9942669,0.00007032775,0.00008611199,0.0006134568,0.0006718297,0.0001709619,0.0003422308,0.00002772145,0.003750513],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1729465,"threshold_uncertainty_score":0.9874267,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03233963132046469,"score_gpt":0.3997946681614323,"score_spread":0.3674550368409676,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}